CARDIAC RETRANSPLANTATION - A VIABLE OPTION

被引:31
作者
KARWANDE, SV [1 ]
ENSLEY, RD [1 ]
RENLUND, DG [1 ]
GAY, WA [1 ]
RICHENBACHER, WE [1 ]
DOTY, DB [1 ]
HAMMOND, ME [1 ]
MARKS, JD [1 ]
COBANOGLU, A [1 ]
MCKEOWN, PP [1 ]
机构
[1] UTAH TRANSPLANT AFFILIATED HOSP,CARDIAC TRANSPLANT PROGRAM,SALT LAKE CITY,UT
关键词
D O I
10.1016/0003-4975(92)90634-G
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate cardiac retransplantation as an appropriate utilization of scarce donor organs we analyzed data from the registry of the International Society for Heart and Lung Transplantation (ISHLT) (n = 449) and the Utah Cardiac Transplant Program (n = 20). Actuarial survival among retransplants was lower than in patients who received only one transplant in both the ISHLT registry patients (1 year survival, 48% versus 78%; p = 0.001) and the Utah series (1 year survival, 74% versus 88%; p = 0.06). Uncontrolled rejection, short interval (<6 months) between transplantations, and the need for mechanical circulatory support were identified as risk factors for retransplantation. The incidence of rejection and infection was similar in first and second transplant recipients. Second transplant recipients had a higher level of sensitization, a greater incidence of donor-specific positive crossmatches, and an increased early mortality. Repetition in the second donor of mismatched HLA antigens present in the first donor did not adversely affect survival. If patients who underwent retransplantation within 6 months of their initial transplantation, those receiving transplants for uncontrolled rejection, and those requiring mechanical assistance were eliminated from the study, the short-term and long-term survival af ter cardiac retransplantation does not diff er from that in patients having a single transplant.
引用
收藏
页码:840 / 845
页数:6
相关论文
共 11 条
[1]   RISK-FACTORS FOR 2ND RENAL-ALLOGRAFTS IMMUNOSUPPRESSED WITH CYCLOSPORINE [J].
ALMOND, PS ;
MATAS, AJ ;
GILLINGHAM, K ;
TROPPMANN, C ;
PAYNE, W ;
DUNN, D ;
SUTHERLAND, D ;
NAJARIAN, JS .
TRANSPLANTATION, 1991, 52 (02) :253-258
[2]  
CABROL C, 1989, TRANSPLANT P, V21, P3658
[3]   RESULTS OF ACUTE HEART RETRANSPLANTATION [J].
DEBOER, J ;
COHEN, B ;
THOROGOOD, J ;
ZANTVOORT, FA ;
DAMARO, J ;
PERSIJN, GG .
LANCET, 1991, 337 (8750) :1158-1158
[4]   CARDIAC RETRANSPLANTATION IN THE CYCLOSPORINE ERA [J].
DEIN, JR ;
OYER, PE ;
STINSON, EB ;
STARNES, VA ;
SHUMWAY, NE .
ANNALS OF THORACIC SURGERY, 1989, 48 (03) :350-355
[5]  
HAMMOND EH, 1991, TRANSPLANT P, V23, P26
[6]   RELATIONSHIP OF OKT3 SENSITIZATION AND VASCULAR REJECTION IN CARDIAC TRANSPLANT PATIENTS RECEIVING OKT3 REJECTION PROPHYLAXIS [J].
HAMMOND, EH ;
WITTWER, CT ;
GREENWOOD, J ;
KNAPE, WA ;
YOWELL, RL ;
MENLOVE, RL ;
CRAVEN, C ;
RENLUND, DG ;
BRISTOW, MR ;
DEWITT, CW ;
OCONNELL, JB .
TRANSPLANTATION, 1990, 50 (05) :776-782
[7]  
HAMMOND EH, 1992, J HEART LUNG TRANSPL, V11, P111
[8]  
KRIETT JM, 1990, J HEART TRANSPLANT, V9, P323
[9]  
KRIETT JM, 1991, J HEART LUNG TRANSPL, V10, P491
[10]  
MICHLER RE, IN PRESS J THORAC CA